Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Copernicus’ Nanoparticle Technology Applied to siRNA

Copernicus Therapeutics, Inc. announced today that at the American Society of Gene Therapy (ASGT) Meeting held in Seattle, Washington, Copernicus showed that the methods used to produce DNA nanoparticles were also very effective when applied to siRNA. Both DNA nanoparticles as well as nanoparticles made with siRNA are highly resistant to degradative processes that would destroy the therapeutic benefit of the nanoparticles. These findings are significant because siRNAs can be designed to block the expression of specific genes and have the potential to treat numerous human diseases, including viral infections. A 2006 Nobel Prize was awarded to the scientists that discovered siRNA.

Copernicus’ Nanoparticle Technology Applied to siRNA

Cleveland, OH | Posted on June 5th, 2007

"We are most enthusiastic about these findings," said Dr. Mark J. Cooper, Sr. Vice President of Science and Medical Affairs at Copernicus. "Our non-viral nucleic acid delivery system provides important safety and efficacy characteristics not seen with viral-based systems. We have extensive experience in the development of DNA nanoparticles, including an encouraging clinical trial in subjects with cystic fibrosis. The data presented at ASGT show that we may be able to expand the use of our non-viral nucleic acid delivery system to the exciting field of siRNA. These results have encouraged us and others to explore the use of our siRNA delivery platform to treat a variety of serious diseases."

"These findings further demonstrate the platform nature of our nucleic acid nanoparticle technology which enables us to develop nucleic acid therapeutics for different parts of the body and for multiple diseases," said Dr. Robert C. Moen, President and CEO of Copernicus. "Our lead DNA nanoparticle program is developing a therapy for a serious disease affecting the lung, cystic fibrosis. Opportunities for siRNA nanoparticles are numerous, and include serious viral lung infections and other genetic disorders."


About Copernicus Therapeutics, Inc.
Copernicus Therapeutics, Inc., a privately held biotechnology company, is advancing novel nucleic acid delivery systems with broad applications in human therapeutics. The Company’s delivery platform can be used to enhance the efficacy and safety of existing drugs as well as to create novel therapeutics.

For more information, please click here

Copernicus Therapeutics, Inc.
Robert C. Moen, M.D., Ph.D., 216-231-0227 x26
President and CEO

Mark J. Cooper, M.D., 216-231-0227 x23
Sr VP, Science and Medical Affairs

Copyright © Business Wire 2007

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press


Chad Mirkin receives nanotechnology prize in Russia October 26th, 2016

Imaging where cancer drugs go in the body could improve treatment October 26th, 2016

New nanomedicine approach aims to improve HIV drug therapies October 24th, 2016

Nanosciences: Genes on the rack October 21st, 2016


Chad Mirkin receives nanotechnology prize in Russia October 26th, 2016

Imaging where cancer drugs go in the body could improve treatment October 26th, 2016

Precise quantum cloning: possible pathway to secure communication: Physicists create best ever quantum clones October 26th, 2016

The quantum sniffer dog: A laser and detector in 1: A microscopic sensor has been developed at TU Wien, which can be used to identify different gases simultaneously October 25th, 2016

The latest news from around the world, FREE

  Premium Products
Only the news you want to read!
 Learn More
University Technology Transfer & Patents
 Learn More
Full-service, expert consulting
 Learn More

Nanotechnology Now Featured Books


The Hunger Project